News
10h
TipRanks on MSNUnited Therapeutics up 7%, Liquidia down 9% in afternoon tradingShares of United Therapeutics (UTHR) and Liquidia (LQDA) are moving sharply in opposite directions in Friday afternoon trading. Shares of United ...
Liquidia Corporation (NASDAQ:LQDA) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 27, BTIG adjusted its price target for Liquidia from $45 to $40 while ...
In a report released yesterday, Andreas Argyrides from Oppenheimer maintained a Sell rating on Liquidia Technologies, with a price target of $6.00. The company’s shares closed yesterday at $19.26.
Arquitos Capital Management gained 13.1% in Q2 2025. Learn how they turned market uncertainty into opportunity with Liquidia ...
Liquidia Technologies is developing LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of PAH. Liquidia PAH provides the commercialization for rare disease pharmaceutical ...
Over the last three years Liquidia has grown its revenue at 1.1% annually. That's not a very high growth rate considering it doesn't make profits. In contrast, the stock has popped 51% per year in ...
Liquidia's PRINT technology will give LIQ861 advantages over Tyvaso, such as: enhancing deep-lung delivery, achieving higher dose levels, and delivered through a disposable dry powder inhaler (DPI').
Liquidia Corporation, a biopharmaceutical company focused on developing therapies for rare cardiopulmonary diseases, announced that it will release its full year 2024 financial results on March 19 ...
Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients ...
MORRISVILLE, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia”) today announced the closing of its previously announced underwritten public offering of ...
Liquidia will present additional data from Cohort A of the ASCENT study during two poster sessions at the American Thoracic Society (ATS) 2025 International Conference on May 21, 2025.
Liquidia's stock was trading at $4.89 Thursday afternoon. According to a statement by the company, the gross proceeds from the deal are expected to bring the company $22.4 million.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results